At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,672 enrolled
Drug / intervention
Tralokinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
In Brief
A Phase 3 clinical trial evaluating Tralokinumab for Atopic Dermatitis. Completed, enrolled 1,672 participants across 309 sites in 11 countries.
Detailed Summary
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesBelgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedJul 2018
Primary CompletionJul 2024
TodayJul 2026
First PostedJul 16, 2018
Enrollment StartMar 18, 2018
Primary CompletionJul 3, 2024
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 8.0 years ago
Interventions
Tralokinumabdrug
Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.